From 20-30% of patients with advanced basal cell carcinoma (BCC) responded to the PD-1 inhibitor cemiplimab (Libtayo) after resistance or intolerance to a hedgehog-pathway inhibitor, according to ...
A discovery with major implications for cancer treatment has been made by a team of researchers from Rensselaer Polytechnic Institute (RPI), the University of Nebraska Medical Center (UNMC), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results